Q: What is Kinectrics’ focus for Canadian operations?
A: Across Canada, Kinectrics has eight locations with offices and specialized laboratory and manufacturing facilities strategically located in Ontario, New Brunswick and Saskatchewan. These locations are in close proximity to generating stations and utility customers, making it easy to provide timely support in the field.
In support of nuclear customers, Kinectrics develops and runs equipment to provide outage and testing support at the stations, builds parts and equipment, and tests and certifies commercial-off-the-shelf equipment. Kinectrics provides full-service design engineering capability for modifications and new designs, and offers the largest and most experienced nuclear safety and licensing firm in Canada.
Many of the labs are located at the head office in Etobicoke, Ontario. Kinectrics also operates facilities near Bruce Power, including the state-of-the-art laundry facility which cleans and repairs personal protective clothing worn in the nuclear stations. The company has a proven track record of investing locally and developing good quality, long terms jobs in professions such as engineering and science, as well as technician and general labour roles.
As the nuclear industry grows in New Brunswick, Kinectrics will look for the opportunity to build facilities here and expand its presence.
Q: Medical isotopes are an important part of cancer care and research. Tell us more.
A: It is exciting to leverage the synergy of clean energy production through nuclear power with life-saving isotope production through its company Isogen, a joint venture between Kinectrics and Framatome. Isogen works with nuclear power operators to enable the production of life-saving medical isotopes. Isogen worked with Bruce Power to design, construct, and commission the first production system to irradiate short-lived medical isotopes using a commercial power reactor. Isogen is currently producing Lutetium-177 (Lu-177), a therapeutic isotope that is very successful in treating prostate cancer and neuroendocrine tumors. Lu-177 destroys cancer cells while leaving healthy cells unaffected.
Kinectrics continues to invest to bring additional isotope production capacity online at Bruce Power, to expand production capabilities to produce other critical medical isotopes beyond Lu-177, and to develop isotope production in other reactor types including certain small modular reactors.